drugset / Trial / NCT05372939
Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Combination With Adalimumab in Subjects with Moderate to Severe Ulcerative Colitis.
Timeline
- Start
- 2021-02-05
- Primary completion
- 2022-06-01
- Completion
- 2022-07-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | VIMEKOFUSP | Protein / enzyme biologic | — | Oral |
| Background | Adalimumab | Monoclonal antibody | — | Subcutaneous |